Waldman v. Spectra Holdco, LLC.

CourtDistrict Court, E.D. New York
DecidedFebruary 6, 2024
Docket1:17-cv-02732
StatusUnknown

This text of Waldman v. Spectra Holdco, LLC. (Waldman v. Spectra Holdco, LLC.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Waldman v. Spectra Holdco, LLC., (E.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK UNITED STATES, STATE OF NEW JERSEY, RAN STATE OF NEW YORK, AND STATE OF vey (NGG “IRC) CONNECTICUT, ~ ( )¢ ) ex rel. MICHAEL WALDMAN, Plaintiff/Relator, -against- SPECTRA HOLDCO, LLC F/K/A SHIEL HOLDINGS LLC AND SPECTRA LABORATORIES, INC., Defendants,

NICHOLAS G. GARAUFIS, United States District Judge. Plaintiff and Relator Michael Waldman (“Plaintiff”) brings this action against his former employers, Defendants Spectra Holdco, LLC, formerly known as Shiel Holdings LLC, (“Shiel”), and Spec- tra Laboratories, Inc. (“Spectra”), (collectively “Defendants”}, alleging violations of the anti-retaliation provision of the False Claims Act (“FCA”), 31 U.S.C. § 3730(h). (See generally Third Amended Complaint (“TAC”) (Dkt. 38) {4 150-52.) Defendants have moved to dismiss the Third Amended Complaint under Fed- eral Rule of Civil Procedure 12(b) (6). (See Not. of Mot, to Dismiss (Dkt. 43); Mem. in Supp. of Mot. to Dismiss (“Mot.”) (Dkt. 43- 1}.) Defendants also move to strike certain allegations made in the Third Amended Complaint as immaterial or prejudicial. (See Mot. at 16.) For the reasons set forth below, Defendants’ motion to dismiss is DENIED. Defendants’ motion to strike is GRANTED in part and DENIED in part.

1 .

I. BACKGROUND! A. Billing Scheme for Diagnostic Medical Tests According to the Third Amended Complaint, Defendant Shiel was a diagnostic medical laboratory business based in Rockleigh, New Jersey that served the greater New York metropolitan area. (TAC 5.) As a provider, Shiel was subject to Medicare and Med- icaid regulations, which required, among other things, submitting documentation of “medical necessity” for diagnostic medical tests with certain diagnosis codes provided by doctors in order to determine coverage and issue reimbursement to the lab for the test. Ud. 6, 44-45, 47.) Not all diagnostic tests, how- ever, are reimbursable; some tests are considered “non-covered” for certain diagnosis codes meaning any claim for reimbursement relating to those tests will be rejected. Ud, § 6.) Accordingly, when ordering a diagnostic test for a Medicare-covered patient, the doctor is supposed to “indicate his or her diagnosis (or sus- pected diagnosis) by providing on the order form (or electronically) the corresponding diagnosis code (or codes) from the International Classification of Diseases and Related Health Problems (“ICD”).” Ud. § 46.) As stated on Shiels website, pro- viders are to choose a code that indicates the medical necessity the doctor believes is appropriate for the test and not to “choose a code merely to secure claim payment.” (/d. { 48.) In the event that Shiel’s Medicare carrier finds a test to be medically unneces- sary, a patient may be required to pay the bill only if an Advance Beneficiary Notice (“ABN”) is signed by the patient acknowledg- ing that the patient agrees to pay out of pocket when Medicare refuses to reimburse. (Id. {{ 50-51.) “Thus, in the normal course of business at a compliant lab,” if Medicare refuses to reimburse

! The following facts are taken from the Third Amended Complaint and, for the purposes of this motion to dismiss, are assumed to be true. See Ark. Pub. Emps. Ret. Sys. v. Bristol-Myers Squibb Co., 28 F.4th 343, 349 (2d Cir. 2022).

a test and the patient has not signed an ABN, the lab will not receive payment for the diagnostic test and have to “eat the cost.” dd. | 52.) B. Defendants’ Alleged Billing Scheme Plaintiff Michael Waldman, who was previously employed by De- fendants as a Senior Sales Representative from November 2012 until December 31, 2017, alleges that Defendants were far from compliant with Medicare and Medicaid regulations. Rather, “Shiel management willfully and intentionally disregarded [Medicare/Medicaid] statutes and regulations” by creating a fraudulent billing scheme aimed at maximizing company reve- nues and personal profit. dd. §{ 8, 26.) Specifically, Plaintiff alleges that Defendants regularly submitted false and fraudulent claims for reimbursement of diagnostic laboratory procedures. (id. § 53.) As part of this scheme, when a claim for reimburse- ment of diagnostic testing was rejected, Shiel’s _ billing department would generate a “Missing Diagnosis Code” report, internally known as “code sheets,” that would be sent to sales reps who were supposed to then take the reports back to the doc- tor’s office to request a covered (and reimbursable) code and sign the report. Ud. 9, 54-59.) Shiel management pressured sales reps to “get the codes done” by any means necessary, including having sales reps and others impermissibly fill out the covered diagnosis codes themselves (id. {{ 14, 62-63); going to the doc- tors’ offices and convincing staff to let them use the doctors’ signature stamps to approve the reports on their own and/or “borrowing” the fax machine to fax the reports back to the billing department as if the reports were completed by the doctor (id. { 14, 64); and forging the doctor’s signature (id. {{ 14, 66). Plaintiff alleges that Shiel offered physicians and their medical practices kickbacks in the form of free goods and services to in- duce referrals. Ud. { 16, 94). These alleged kickbacks took the form of all new Apple computers and software that did not fall

within any regulatory safe harbor to be recognized as legitimate medical equipment (id. 1 95-96); gift cards and expensive lunches or dinners (id. 16, 99-100, 102); sports tickets (id. 4] 16, 101); and free services such as sending phlebotomists (whose ostensible purpose was to collect blood samples) to doctors’ of- fices to handle unrelated office tasks that fell outside of regulatory safe harbors established by the U.S. Department of Health and Human Services and the Office of the Inspector Gen- □ eral for phlebotomists (id. 41 17, 97). Employees often “faked receipts” to get reimbursement for these expenses. (id. { 16.) Plaintiff alleges that management pressured and incentivized the sales team to engage in this fraudulent conduct by rewarding “compliant” staff members with free meals and other gratuities. (id. 14, 65). Shiel also provided incentive compensation for its sales reps, whereby sales reps and certain employees tasked with servicing customer relationships received a percentage of col- lected revenues from lab tests ordered by their customers. (Id. { 13.) As part of their compensation, sales reps could be rewarded with up to ten percent of revenues collected as a commission or bonus. (id. § 88.) Client service reps, who handled matters for existing customers, could obtain up to two percent of revenues. (id.) Shiel management used these incentives to pressure sales teps to “get the codes done” by “constantly remind[ing] them how much money the uncompleted reports represented to the reps in lost commission.” (id. (4 90-93.) If sales reps failed to meet their quotas and targets, management would reprimand them through verbal chastising and criticism, and/or use threats of demotion, pay cuts, or even termination. (Id. {| 12, 88.)?

2 Plaintiff also asserts that the sheer volume of the code sheets (upwards of thousands of pages), coupled with (1) constant demands to get the re- ports done in short timeframes (e.g., by end of the week or even within a day), and (2) busy doctors who complained that they had no time to go over so many reports, made it physically impossible for sales reps to get

C. Retaliation 1. Plaintiff Alerts Management to Potential Fraudulent Billing Scheme Plaintiff alleges that Defendants retaliated against him for refus- ing to engage in their fraudulent billing scheme. (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Liburd v. Bronx Lebanon Hospital Center
372 F. App'x 137 (Second Circuit, 2010)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Arthur Hollander v. American Cyanamid Co.
895 F.2d 80 (Second Circuit, 1990)
Fink v. Time Warner Cable
714 F.3d 739 (Second Circuit, 2013)
Espinal v. Goord
558 F.3d 119 (Second Circuit, 2009)
Hayden v. Paterson
594 F.3d 150 (Second Circuit, 2010)
Campbell v. Grayline Air Shuttle, Inc.
930 F. Supp. 794 (E.D. New York, 1996)
Johnson v. THE UNIVERSITY OF ROCHESTER MEDICAL CENTER
686 F. Supp. 2d 259 (W.D. New York, 2010)
Weslowski v. Zugibe
626 F. App'x 20 (Second Circuit, 2015)
Biocad JSC v. F. Hoffmann-La Roche Ltd.
942 F.3d 88 (Second Circuit, 2019)
Cowell v. Utopia Home Care, Inc.
144 F. Supp. 3d 398 (E.D. New York, 2015)
United States ex rel. Wood v. Allergan, Inc.
899 F.3d 163 (Second Circuit, 2018)
Abrams v. Department of Public Safety
764 F.3d 244 (Second Circuit, 2014)
Vega v. Hempstead Union Free School District
801 F.3d 72 (Second Circuit, 2015)
United States ex rel. Klein v. Empire Education Corp.
959 F. Supp. 2d 248 (N.D. New York, 2013)
Lynch v. Southampton Animal Shelter Foundation Inc.
278 F.R.D. 55 (E.D. New York, 2011)
Grant v. Bethlehem Steel Corp.
622 F.2d 43 (Second Circuit, 1980)

Cite This Page — Counsel Stack

Bluebook (online)
Waldman v. Spectra Holdco, LLC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/waldman-v-spectra-holdco-llc-nyed-2024.